Pier 88 Investment Partners LLC Has $1.44 Million Stock Position in Schrödinger, Inc. (NASDAQ:SDGR)

Pier 88 Investment Partners LLC lessened its holdings in Schrödinger, Inc. (NASDAQ:SDGR) by 3.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 74,720 shares of the company’s stock after selling 2,410 shares during the period. Pier 88 Investment Partners LLC owned 0.10% of Schrödinger worth $1,441,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Paradigm Asset Management Co. LLC acquired a new stake in shares of Schrödinger in the fourth quarter worth about $50,000. Quarry LP lifted its holdings in Schrödinger by 1,150.0% in the 3rd quarter. Quarry LP now owns 2,825 shares of the company’s stock worth $52,000 after purchasing an additional 2,599 shares during the last quarter. GAMMA Investing LLC boosted its position in Schrödinger by 87.5% during the fourth quarter. GAMMA Investing LLC now owns 2,796 shares of the company’s stock worth $54,000 after purchasing an additional 1,305 shares during the period. KBC Group NV grew its holdings in Schrödinger by 73.9% during the fourth quarter. KBC Group NV now owns 4,361 shares of the company’s stock valued at $84,000 after purchasing an additional 1,853 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Schrödinger in the third quarter worth $102,000. 79.05% of the stock is currently owned by institutional investors.

Schrödinger Stock Performance

NASDAQ SDGR opened at $19.96 on Monday. Schrödinger, Inc. has a twelve month low of $16.67 and a twelve month high of $29.15. The stock has a market cap of $1.46 billion, a PE ratio of -8.53 and a beta of 1.62. The firm has a 50-day simple moving average of $23.11 and a 200 day simple moving average of $20.79.

Schrödinger (NASDAQ:SDGR) last announced its quarterly earnings data on Wednesday, February 26th. The company reported ($0.55) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.20). The firm had revenue of $88.32 million during the quarter, compared to the consensus estimate of $83.20 million. Schrödinger had a negative return on equity of 35.77% and a negative net margin of 91.84%. Research analysts forecast that Schrödinger, Inc. will post -2.37 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

SDGR has been the topic of a number of research analyst reports. Piper Sandler lowered their target price on shares of Schrödinger from $50.00 to $45.00 and set an “overweight” rating on the stock in a research note on Thursday, February 27th. KeyCorp raised their price target on Schrödinger from $25.00 to $27.00 and gave the company an “overweight” rating in a research report on Friday, January 24th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $32.29.

Insider Buying and Selling at Schrödinger

In other Schrödinger news, CFO Geoffrey Craig Porges sold 5,491 shares of Schrödinger stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $21.76, for a total transaction of $119,484.16. Following the sale, the chief financial officer now directly owns 27,544 shares of the company’s stock, valued at approximately $599,357.44. The trade was a 16.62 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 8.60% of the company’s stock.

Schrödinger Company Profile

Schrödinger, Inc, together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries.